HSBC Holdings’s Mereo BioPharma MREO Stock Holding History

HSBC Holdings’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-13,577	Closed	-$29.8K	–	3160
2025 Q1	$29.8K	Hold	13,577	–	–	﹤0.01%	2950
2024 Q4	$47.5K	Sell	13,577 -15,000	-52%	-$58.9K	﹤0.01%	2995
2024 Q3	$116K	Hold	28,577	–	–	﹤0.01%	2771
2024 Q2	$99.6K	Hold	28,577	–	–	﹤0.01%	2730
2024 Q1	$94.3K	Sell	28,577 -29,640	-51%	-$100K	﹤0.01%	2853
2023 Q4	$134K	Hold	58,217	–	–	﹤0.01%	2545
2023 Q3	$75.1K	Hold	58,217	–	–	﹤0.01%	2588
2023 Q2	$76.8K	Hold	58,217	–	–	﹤0.01%	2464
2023 Q1	$40.9K	Hold	58,217	–	–	﹤0.01%	2577
2022 Q4	$43.1K	Hold	58,217	–	–	﹤0.01%	2978
2022 Q3	$52K	Hold	58,217	–	–	﹤0.01%	2812
2022 Q2	$72K	Hold	58,217	–	–	﹤0.01%	3091
2022 Q1	$65K	Hold	58,217	–	–	﹤0.01%	3176
2021 Q4	$95K	Hold	58,217	–	–	﹤0.01%	3147
2021 Q3	$137K	Hold	58,217	–	–	﹤0.01%	2847
2021 Q2	$180K	Hold	58,217	–	–	﹤0.01%	2778
2021 Q1	$196K	Hold	58,217	–	–	﹤0.01%	2553
2020 Q4	$211K	Buy	+58,217	New	+$146K	﹤0.01%	2790

Other funds holding MREO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HSBC Holdings's MREO Position: Q2 2025 in Review

HSBC Holdings sold out of Mereo BioPharma (MREO) in Q2 2025, closing a stake of 13,577 shares — an estimated $29.8K sold.

HSBC Holdings first reported a position in MREO in Q4 2020 and held it in 18 quarters. The position peaked at $211K in Q4 2020. 86 funds tracked by Wall St. Rank hold MREO as of Q2 2025.

HSBC Holdings reported no remaining Mereo BioPharma position as of Q2 2025 after selling out during the quarter.
HSBC Holdings sold 13,577 Mereo BioPharma shares in Q2 2025, an estimated $29.8K.
HSBC Holdings first reported a position in Mereo BioPharma in Q4 2020 and held it in 18 quarters.
HSBC Holdings's Mereo BioPharma position peaked at $211K in Q4 2020.
86 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2025.

Based on HSBC Holdings's 13F filing for Q2 2025, filed 13 Aug 2025.